Alejandra Bernardini

Alejandra Bernardini

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2016 in Microorganisms
Verified
Journal Article
Open access
PDF file
PBPaula Blanco
Paula Blanco
SHSara Hernando-Amado
Sara Hernando-Amado
JRJose Antonio Reales-Calderon
Jose Antonio Reales-Calderon
FPFernando Corona Pajares
Fernando Corona Pajares
FLFelipe Lira
Felipe Lira
JMJose Martinez
Jose Martinez
Bacterial multidrug efflux pumps are antibiotic resistance determinants present in all microorganisms. With few exceptions, they are chromosomally encoded and present a conserved organization both at the genetic and at the protein levels. In addition, most, if not all, strains of a given bacterial species present the same chromosomally-encoded efflux pumps. Altogether this indicates that multidrug efflux pumps are ancient elements encoded in bacterial genomes long before the recent use of antibiotics for human and animal therapy. In this regard, it is worth mentioning that efflux pumps can extrude a wide range of substrates that include, besides antibiotics, heavy metals, organic pollutants, plant-produced compounds, quorum sensing signals or bacterial metabolites, among others. In the current review, we present information on the different functions that multidrug efflux pumps may have for the bacterial behaviour in different habitats as well as on their regulation by specific signals. Since, in addition to their function in non-clinical ecosystems, multidrug efflux pumps contribute to intrinsic, acquired, and phenotypic resistance of bacterial pathogens, the review also presents information on the search for inhibitors of multidrug efflux pumps, which are currently under development, in the aim of increasing the susceptibility of bacterial pathogens to antibiotics.

3 July 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CSCristina Segovia
Cristina Segovia
EJEdurne San José
Edurne San José
EMEster Munera-Maravilla
Ester Munera-Maravilla
MMMónica Martínez-Fernández
Mónica Martínez-Fernández
LGLeire Garate
Leire Garate
JESÚS M ParamioJESÚS M Paramio
JESÚS M Paramio

1 January 2013 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JOJorge Olivares
Jorge Olivares
ABAlejandra Bernardini
Alejandra Bernardini
GGGuillermo Garcia-Leon
Guillermo Garcia-Leon
FPFernando Corona Pajares
Fernando Corona Pajares
MSMaria B. Sanchez
Maria B. Sanchez
JMJose Martinez
Jose Martinez
Intrinsically resistant bacteria have emerged as a relevant health problem in the last years. Those bacterial species, several of them with an environmental origin, present naturally a low-level susceptibility to several drugs. It has been proposed that intrinsic resistance is mainly the consequence of the impermeability of cellular envelopes, the activity of multidrug efflux pumps or the lack of appropriate targets for a given family of drugs. However, recently published articles indicate that the characteristic phenotype of susceptibility to antibiotics of a given bacterial species depends on the concerted activity of several elements, what has been named as intrinsic resistome. These determinants comprise not just classical resistance genes. Other elements, several of them involved in basic bacterial metabolic processes, are of relevance for the intrinsic resistance of bacterial pathogens. In the present review we analyse recent publications on the intrinsic resistomes of Escherichia coli and Pseudomonas aeruginosa. We present as well information on the role that global regulators of bacterial metabolism, as Crc from P. aeruginosa, may have on modulating bacterial susceptibility to antibiotics. Finally, we discuss the possibility of searching inhibitors of the intrinsic resistome in the aim of improving the activity of drugs currently in use for clinical practice.

1 August 2011 in Theriogenology
Verified
Journal Article
Closed access
ABAlejandra Bernardini
Alejandra Bernardini
FHF. Hozbor
F. Hozbor
ESE. Sanchez
E. Sanchez
MFM.W. Fornés
M.W. Fornés
RAR.H. Alberio
R.H. Alberio
ACA. Cesari
A. Cesari

Verified
Journal Article
Open access
PDF file
ILIris Lodewijk
Iris Lodewijk
MDMarta Dueñas
Marta Dueñas
CRCarolina Rubio
Carolina Rubio
EMEster Munera-Maravilla
Ester Munera-Maravilla
CACristina Segovia de Andrés
Cristina Segovia de Andrés
CSCristian Suárez-Cabrera
Cristian Suárez-Cabrera
Bladder Cancer (BC) represents a clinical and social challenge due to its high incidence and recurrence rates, as well as the limited advances in effective disease management. Currently, a combination of cytology and cystoscopy is the routinely used methodology for diagnosis, prognosis and disease surveillance. However, both the poor sensitivity of cytology tests as well as the high invasiveness and big variation in tumour stage and grade interpretation using cystoscopy, emphasizes the urgent need for improvements in BC clinical guidance. Liquid biopsy represents a new non-invasive approach that has been extensively studied over the last decade and holds great promise. Even though its clinical use is still compromised, multiple studies have recently focused on the potential application of biomarkers in liquid biopsies for BC, including circulating tumour cells and DNA, RNAs, proteins and peptides, metabolites and extracellular vesicles. In this review, we summarize the present knowledge on the different types of biomarkers, their potential use in liquid biopsy and clinical applications in BC.

1 January 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CRCarolina Rubio
Carolina Rubio
MMMónica Martínez-Fernández
Mónica Martínez-Fernández
CSCristina Segovia
Cristina Segovia
ILIris Lodewijk
Iris Lodewijk
CSCristian Suárez-Cabrera
Cristian Suárez-Cabrera
JESÚS M ParamioJESÚS M Paramio
JESÚS M Paramio
Purpose: Bladder cancer (BC) is a clinical and social problem due to its high incidence and recurrence rates. It frequently appears in elderly patients showing other medical comorbidities that hamper the use of standard chemotherapy. We evaluated the activity of CDK4/6 inhibitor as a new therapy for patients unfit for cisplatin (CDDP). Experimental Design: BC cell lines were tested for in vitro sensitivity to CDK4/6 inhibition. A novel metastatic BC mouse model was developed and used to test its in vivo activity. Results: Cell lines tested were sensitive to CDK4/6 inhibition, independent on RB1 gene status. Transcriptome analyses and knockdown experiments revealed a major role for FOXM1 in this response. CDK4/6 inhibition resulted in reduced FOXM1 phosphorylation in vitro and in vivo and showed synergy with CDDP, allowing a significant tumor regression. FOXM1 exert important oncogenic roles in BC. Conclusions: CDK4/6 inhibitors, alone or in combination, are a novel therapeutic strategy for advanced BC patients previously classified as unfit for current treatment options.